Physician profile
Kevin E Elder
NPI 1598768160
$7,708.71
in general payments reported to CMS, 2019-2025
28 companies · $481 in 2025
The $481 reported for 2025 was more than what 82% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $687 · 2020: $2,415 · 2021: $55.19 · 2022: $3,735 · 2023: $335 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $816.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $5,529.62 | 2020-2022 | |
| Mvp Orthopedics INC | $339.80 | 2020-2023 | |
| Coastal Medical Technologies LLC | $207.09 | 2023 | |
| Novo Nordisk INC | $168.54 | 2019-2020 | |
| Medtronic, INC. | $159.76 | 2025 | Mazor X System, O-Arm |
| Amgen INC. | $150.05 | 2019 | |
| Penumbra, INC. | $149.46 | 2023-2025 | Indigo System |
| Bioventus LLC | $139.75 | 2022-2025 | Xcell |
| Abbvie INC. | $121.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $105.69 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $95.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $62.59 | 2019-2020 | |
| Lilly USA, LLC | $49.93 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.73 | 2019-2020 | |
| Amarin Pharma, INC. | $47.84 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $42.72 | 2019-2020 | |
| Ibsa Pharma INC. | $42.00 | 2019-2025 | Licart, Tirosint, Flector |
| Theragen, INC. | $38.09 | 2021-2023 | Kneehab Xp |
| Arbor Pharmaceuticals, INC. | $32.69 | 2019-2020 | |
| Pfizer INC. | $29.92 | 2019-2020 | |
| Arteriocyte Medical Systems, INC. | $22.38 | 2021 | |
| Gilead Sciences, INC. | $20.35 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.23 | 2019 | |
| Redhill Biopharma INC. | $19.07 | 2020 | |
| Endo Pharmaceuticals INC. | $17.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $17.86 | 2023 | Seglentis |
| Allergan, INC. | $14.71 | 2020 | |
| Fidia Pharma USA INC. | $14.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.